ImmunityBio (IBRX) Current Deferred Revenue (2014 - 2018)
ImmunityBio (IBRX) posted quarterly Current Deferred Revenue of $598000.0 for Q4 2018, up 15.0% year-over-year from $520000.0 in Q4 2017, and up 3.64% quarter-over-quarter from $577000.0 in Q3 2018.
Powered by 
Analysis
ImmunityBio (IBRX) Current Deferred Revenue (2014 - 2018) Analysis & Trends
ImmunityBio (IBRX) has reported Current Deferred Revenue for 5 consecutive years, with $598000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Current Deferred Revenue rose 15.0% year-over-year to $598000.0; the TTM figure through Dec 2018 stood at $598000.0 (up 15.0% YoY), while the FY2018 annual figure was $598000.0, up 15.0% from the prior year.
- Current Deferred Revenue climbed to $598000.0 in Q4 2018 per IBRX's latest filing, from $577000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $598000.0 in Q4 2018 and bottomed at $5000.0 in Q4 2015.
- Historically, Current Deferred Revenue has averaged $407538.5 across 5 years, with a median of $501000.0 in 2017.
- Annual changes were most pronounced in 2015 — Current Deferred Revenue plunged 99.04% — and 2016, when it jumped 3840.0%.
- ImmunityBio's Current Deferred Revenue stood at $521000.0 in 2014, then slumped by 99.04% to $5000.0 in 2015, then surged by 3840.0% to $197000.0 in 2016, then surged by 163.96% to $520000.0 in 2017, then grew by 15.0% to $598000.0 in 2018.
- Business Quant data shows IBRX's Current Deferred Revenue at $598000.0 in Q4 2018, $577000.0 in Q3 2018, and $558000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.48 Bn | 8.12 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 598,000.00 |
| Sep 30, 2018 | 577,000.00 |
| Jun 30, 2018 | 558,000.00 |
| Mar 31, 2018 | 539,000.00 |
| Dec 31, 2017 | 520,000.00 |
| Sep 30, 2017 | 501,000.00 |
| Jun 30, 2017 | 484,000.00 |
| Mar 31, 2017 | 215,000.00 |
| Dec 31, 2016 | 197,000.00 |
| Dec 31, 2015 | 5,000.00 |
| Sep 30, 2015 | 342,000.00 |
| Jun 30, 2015 | 241,000.00 |
| Dec 31, 2014 | 521,000.00 |